$62.2 M

BLPH Mkt cap, 04-Dec-2018
Bellerophon Therapeutics Net income (Q2, 2018)-11.5 M
Bellerophon Therapeutics EBIT (Q2, 2018)-7.9 M
Bellerophon Therapeutics Cash, 30-Jun-201823.4 M

Bellerophon Therapeutics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

R&D expense

33.4m16.7m17.9m

General and administrative expense

14.9m7.1m6.7m

Operating expense total

48.2m23.8m24.6m

EBIT

(46.6m)(23.8m)(24.6m)

Interest income

109.0k95.0k184.0k

Income tax expense

(438.0k)

Net Income

(46.5m)(23.8m)(54.8m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

R&D expense

9.5m8.4m7.1m5.1m4.0m2.5m3.3m8.0m4.4m6.4m5.8m

General and administrative expense

4.6m3.4m4.3m2.0m1.2m1.7m1.4m3.1m1.7m2.1m2.1m

Operating expense total

14.1m11.9m11.4m7.1m5.2m4.2m4.8m11.1m6.2m8.5m7.9m

EBIT

(12.9m)(11.6m)(11.2m)(7.1m)(5.2m)(4.2m)(4.8m)(11.1m)(6.2m)(8.5m)(7.9m)

Interest income

19.0k27.0k27.0k30.0k22.0k22.0k27.0k53.0k33.0k99.0k91.0k

Income tax expense

5.4m5.4m

Net Income

(12.9m)(11.6m)(11.1m)(7.1m)(5.1m)(4.2m)(19.1m)(23.1m)(7.6m)4.1m(11.5m)

Bellerophon Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

6.3m14.5m28.8m

Current Assets

29.5m26.5m35.6m

PP&E

1.8m1.4m1.0m

Total Assets

38.4m29.7m36.8m

Accounts Payable

1.6m2.8m3.9m

Current Liabilities

8.1m6.5m7.1m

Total Liabilities

8.1m11.7m39.4m

Additional Paid-in Capital

130.9m142.2m176.2m

Retained Earnings

(100.7m)(124.5m)(179.3m)

Total Equity

18.0m(2.6m)

Financial Leverage

1.7 x-14.2 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

62.9m48.5m23.9m1.3m1.3m3.9m13.5m11.0m32.3m28.4m23.4m

Current Assets

73.6m60.9m46.9m23.1m18.6m17.5m23.2m20.4m39.4m34.8m28.8m

PP&E

1.6m1.5m1.8m1.7m1.6m1.5m1.3m1.2m1.1m935.0k845.0k

Total Assets

75.2m62.4m49.2m31.2m26.3m22.8m25.8m22.4m40.9m35.9m29.8m

Accounts Payable

659.0k966.0k934.0k641.0k2.0m2.2m3.9m2.8m2.8m4.6m4.1m

Current Liabilities

12.8m11.2m8.6m7.3m6.2m4.8m6.1m5.5m6.4m8.4m9.0m

Total Liabilities

11.2m8.6m7.3m23.1m25.2m33.7m37.6m

Additional Paid-in Capital

131.5m132.8m134.9m144.1m146.4m170.3m176.9m178.3m

Retained Earnings

(67.1m)(78.7m)(89.9m)(107.7m)(112.9m)(117.1m)(143.6m)(147.6m)(155.2m)(175.2m)(186.7m)

Total Equity

23.9m20.1m18.0m800.0k(787.0k)15.7m2.2m(7.8m)

Financial Leverage

1.3 x1.3 x1.3 x32.2 x-28.4 x2.6 x16.2 x-3.8 x

Bellerophon Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016

Net Income

(46.5m)(23.8m)

Depreciation and Amortization

(377.0k)(400.0k)

Cash From Operating Activities

(46.3m)(17.2m)

Cash From Investing Activities

(18.3m)12.2m

Cash From Financing Activities

54.0m13.2m

Free Cash Flow

(46.7m)(17.2m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(12.9m)(24.5m)(35.6m)(7.1m)(5.1m)(4.2m)(19.1m)(23.1m)(30.7m)4.1m(7.4m)

Depreciation and Amortization

183.0k273.0k104.0k192.0k283.0k91.0k181.0k

Accounts Payable

659.0k966.0k934.0k641.0k2.0m2.2m3.9m(796.0k)(552.0k)

Cash From Operating Activities

(18.0m)(29.0m)(6.7m)(8.2m)(11.2m)(444.0k)(6.1m)

Cash From Investing Activities

(4.2m)(17.8m)1.7m1.7m2.4m502.0k

Cash From Financing Activities

53.9m53.9m3.0m26.7m(28.0k)141.0k

Free Cash Flow

(29.4m)(6.7m)

Bellerophon Therapeutics Ratios

USDY, 2018

Financial Leverage

-3.8 x
Report incorrect company information

Bellerophon Therapeutics Employee Rating

1.01 votes
Culture & Values
N/A
Work/Life Balance
N/A
Senior Management
N/A
Salary & Benefits
N/A
Career Opportunities
N/A
Sourcewdxefcqufszuzezftuxetqsqxt